Repligen vs 10x Genomics
Repligen and 10x Genomics are similar in size: $738m and $643m of revenue in their latest fiscal years. Repligen grew faster (16.4% against 5.2%). Repligen kept more of each dollar of sales as profit: a net margin of 6.6% against -6.8%. 10x Genomics carries less debt relative to equity (0.0% against 25.7%).
| Latest fiscal year | RepligenRGEN, 2025 | 10x GenomicsTXG, 2025 |
|---|---|---|
| Revenue | $738m | $643m |
| Revenue growth | 16.4% | 5.2% |
| Net income | $48.9m | −$43.5m |
| Operating margin | 7.5% | -9.5% |
| Net margin | 6.6% | -6.8% |
| Return on equity | 2.4% | -5.8% |
| Free cash flow | $93.9m | $130m |
| Cash | $566m | $474m |
| Total debt | $542m | $0 |
| Debt to equity | 25.7% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 2,000 | — |
| Market value | $10.13bn | $8.34bn |
| Price vs our value range | Above our value range | — |
| Moat score | 39 (Weak) | 33 (Weak) |
| Insider trades, 12 months | 0 buys, 25 sales | 0 buys, 50 sales |